Dublin, April 30, 2026 (GLOBE NEWSWIRE) — The “Deoxycholic Acid Obesity Drugs Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The deoxycholic acid obesity drugs market is witnessing robust growth, with projections indicating a rise from $0.5 billion in 2025 to $0.57 billion in 2026, registering a compound annual growth rate (CAGR) of 14.4%. This growth is largely driven by factors such as the escalation in consumer awareness regarding aesthetic treatments, the expansion of medical aesthetics clinics, and the increasing acceptance of minimally invasive procedures. Additionally, a surge in disposable income and the availability of approved deoxycholic acid formulations are contributing to this upward trend.
Looking forward, the market is anticipated to expand to $0.97 billion by 2030, with a CAGR of 14.1%. This forecasted growth can be attributed to the climbing demand for personalized aesthetic treatments, the augmentation of combination aesthetic protocols, and a sharper focus on body contouring procedures. Investments in aesthetic drug innovation and enhanced market penetration in emerging regions are also significant contributors. Key trends include a growing inclination towards non-surgical fat reduction procedures, increased development of combination lipolytic therapies, and a heightened priority on achieving patient-specific aesthetic results.
The escalating rates of obesity are a major growth driver for the deoxycholic acid obesity drugs market. Factors leading to increased obesity include unhealthy dietary habits characterized by high consumption of processed foods and sugary drinks, resulting in excessive body fat accumulation. Deoxycholic acid obesity drugs facilitate fat reduction by breaking down surplus fat cells. For instance, the UK government reported that 64.5% of adults in England were classified as overweight or obese in 2023-24, up from 64% in 2022-23. This spike in obesity is expected to bolster the market further.
The burgeoning demand for non-surgical body contouring solutions is also a critical factor driving market growth. These solutions, which utilize advanced technologies like cryolipolysis and ultrasound, offer effective fat reduction without surgery. Deoxycholic acid drugs play an essential role in non-surgical contouring by breaking down fat cells in targeted areas, thus enhancing body shape without invasive procedures. According to the International Society of Aesthetic Plastic Surgery, procedures such as botulinum toxin injections and hyaluronic acid treatments have surged, indicating a strong market trajectory.
Leading companies in the deoxycholic acid obesity drug sector are focusing on the development of advanced products, like injectable solutions, to improve treatment efficacy. For example, LG Chem Ltd.’s Bellacholine, launched in March 2024, targets submental fat and capitalizes on deoxycholic acid’s fat-breaking properties to achieve desired results.
Prominent companies in this market include AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, and Daewoong Pharmaceutical, to name a few. North America currently leads the market, but Asia-Pacific is poised to witness the fastest growth. Notably, tariffs are impacting the market by increasing the costs associated with imported pharmaceutical components, although they are simultaneously encouraging local production and regional supply chain efficiency.
This market research report delivers a comprehensive overview of current and future scenarios within the deoxycholic acid obesity drugs industry, offering insights into market size, regional shares, competitive landscape, and emerging opportunities.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $0.57 Billion |
| Forecasted Market Value (USD) by 2030 | $0.97 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
Major Trends
- Increasing Adoption of Non-Surgical Fat Reduction Procedures
- Rising Demand for Injectable Aesthetic Treatments
- Growing Development of Combination Lipolytic Therapies
- Expansion of Clinic-Based Body Contouring Services
- Enhanced Focus on Patient-Specific Aesthetic Outcomes
Report Scope
Markets Covered:
- Drug Type: ATX-101; Experimental formulations; Combination therapies; Oral products
- Formulation: Injectable; Topical
- Distribution Channel: Direct Sales; Retail Pharmacies; Online Pharmacies
- Application: Fat reduction and management
- End-User: Aesthetic clinics to home administration
Subsegments:
- ATX-101: Standard and high-purity forms; Combination therapies
- Experimental Formulations: Clinical trial and customized formulations
- Combination Therapies: Lipolytic agents and enzyme therapy
- Oral Products: Capsules, tablets, liquid formulations
Key Companies:
- AbbVie Inc
- Cipla Ltd
- Glenmark Life Sciences Ltd.
Companies Featured
- AbbVie Inc.
- Cipla Ltd.
- Glenmark Life Sciences Limited
- Curia Global Inc.
- Daewoong Pharmaceutical Co. Ltd.
- Actylis
- ICE Pharma
- Cayman Chemical Company
- Nacalai Tesque Inc.
- Sichuan Huiyu Pharmaceutical
- Conscientia Industrial
- Manus Aktteva Biopharma LLP
- Jeevan Chemicals & Pharmaceuticals
- Anhui Chem-Bright Bioengineering Co. Ltd.
- GlpBio Technology LLC
- Legere Pharmaceuticals
- Otto Chemie Pvt. Ltd.
- BOC Sciences
- Guangzhou Green Cross Pharmaceutical
- Prodotti Chimici e Alimentari S.P.A
For more information about this report visit https://www.researchandmarkets.com/r/bpfupx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Deoxycholic Acid Obesity Drugs Market
